How Ligands Illuminate GPCR Molecular Pharmacology

Cell

Volumn 170, Issue 3, 2017, Pages 414-427

  Wacker, Daniel ^a   Stevens, Raymond C ^b   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATYPICAL ANTIPSYCHOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINACALCET; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; MARAVIROC; OPIATE; SEROTONIN 1D AGONIST; SONIDEGIB; VISMODEGIB; LIGAND;

BINDING SITE; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN GENOME; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85026367955     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.07.009     Document Type: Review

References (111)

1. Airan, R.D., Thompson, K.R., Fenno, L.E., Bernstein, H., Deisseroth, K., Temporally precise in vivo control of intracellular signalling. Nature 458 (2009), 1025–1029.
2. Aitken, M., Berndt, E.R., Cutler, D.M., Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff. (Millwood) 28 (2009), w151–w160.
3. Alexander, S.P., Davenport, A.P., Kelly, E., Marrion, N., Peters, J.A., Benson, H.E., Faccenda, E., Pawson, A.J., Sharman, J.L., Southan, C., Davies, J.A., CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br. J. Pharmacol. 172 (2015), 5744–5869.
4. Allen, J.A., Roth, B.L., Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 51 (2011), 117–144.
5. Allen, J.A., Yost, J.M., Setola, V., Chen, X., Sassano, M.F., Chen, M., Peterson, S., Yadav, P.N., Huang, X.P., Feng, B., et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. USA 108 (2011), 18488–18493.
6. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M.C., Cesarman, E., Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385 (1997), 347–350.
7. Asano, T., Katada, T., Gilman, A.G., Ross, E.M., Activation of the inhibitory GTP-binding protein of adenylate cyclase, Gi, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J. Biol. Chem. 259 (1984), 9351–9354.
8. Benovic, J.L., DeBlasi, A., Stone, W.C., Caron, M.G., Lefkowitz, R.J., Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science 246 (1989), 235–240.
9. Black, J.W., Leff, P., Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220 (1983), 141–162.
10. Brown, A.J., Goldsworthy, S.M., Barnes, A.A., Eilert, M.M., Tcheang, L., Daniels, D., Muir, A.I., Wigglesworth, M.J., Kinghorn, I., Fraser, N.J., et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278 (2003), 11312–11319.
11. Bunzow, J.R., Sonders, M.S., Arttamangkul, S., Harrison, L.M., Zhang, G., Quigley, D.I., Darland, T., Suchland, K.L., Pasumamula, S., Kennedy, J.L., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60 (2001), 1181–1188.
12. Burns, C.M., Chu, H., Rueter, S.M., Hutchinson, L.K., Canton, H., Sanders-Bush, E., Emeson, R.B., Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387 (1997), 303–308.
13. Carlsson, J., Coleman, R.G., Setola, V., Irwin, J.J., Fan, H., Schlessinger, A., Sali, A., Roth, B.L., Shoichet, B.K., Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7 (2011), 769–778.
14. Cerione, R.A., Codina, J., Benovic, J.L., Lefkowitz, R.J., Birnbaumer, L., Caron, M.G., The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 23 (1984), 4519–4525.
15. Changeux, J.P., Christopoulos, A., Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. Cell 166 (2016), 1084–1102.
16. Chidiac, P., Hebert, T.E., Valiquette, M., Dennis, M., Bouvier, M., Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 45 (1994), 490–499.
17. Chien, E.Y., Liu, W., Zhao, Q., Katritch, V., Han, G.W., Hanson, M.A., Shi, L., Newman, A.H., Javitch, J.A., Cherezov, V., Stevens, R.C., Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330 (2010), 1091–1095.
18. Christopher, J.A., Aves, S.J., Bennett, K.A., Doré, A.S., Errey, J.C., Jazayeri, A., Marshall, F.H., Okrasa, K., Serrano-Vega, M.J., Tehan, B.G., et al. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J. Med. Chem. 58 (2015), 6653–6664.
19. Christopoulos, A., Changeux, J.P., Catterall, W.A., Fabbro, D., Burris, T.P., Cidlowski, J.A., Olsen, R.W., Peters, J.A., Neubig, R.R., Pin, J.P., et al. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66 (2014), 918–947.
20. Clark, A.J., The antagonism of acetyl choline by atropine. J. Physiol. 61 (1926), 547–556.
21. Congreve, M., Andrews, S.P., Doré, A.S., Hollenstein, K., Hurrell, E., Langmead, C.J., Mason, J.S., Ng, I.W., Tehan, B., Zhukov, A., et al. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J. Med. Chem. 55 (2012), 1898–1903.
22. Cooper, M.K., Porter, J.A., Young, K.E., Beachy, P.A., Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280 (1998), 1603–1607.
23. Coughlin, S.R., Thrombin signalling and protease-activated receptors. Nature 407 (2000), 258–264.
24. De Lean, A., Stadel, J.M., Lefkowitz, R.J., A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255 (1980), 7108–7117.
25. DeWire, S.M., Violin, J.D., Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ. Res. 109 (2011), 205–216.
26. DeWire, S.M., Yamashita, D.S., Rominger, D.H., Liu, G., Cowan, C.L., Graczyk, T.M., Chen, X.T., Pitis, P.M., Gotchev, D., Yuan, C., et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344 (2013), 708–717.
27. Dillon, G.M., Lubbers, L.S., Ferguson, M.T., Lao, J.Z., Huang, R.R., Xiao, J.C., Fong, T.M., Hale, J.J., Rupprecht, K., Miao, S., et al. MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice. Behav. Pharmacol. 22 (2011), 91–100.
28. Dror, R.O., Pan, A.C., Arlow, D.H., Borhani, D.W., Maragakis, P., Shan, Y., Xu, H., Shaw, D.E., Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 108 (2011), 13118–13123.
29. Elkins, J.M., Fedele, V., Szklarz, M., Abdul Azeez, K.R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.P., Roth, B.L., et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nat. Biotechnol. 34 (2016), 95–103.
30. Farrens, D.L., Altenbach, C., Yang, K., Hubbell, W.L., Khorana, H.G., Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996), 768–770.
31. Fenalti, G., Giguere, P.M., Katritch, V., Huang, X.P., Thompson, A.A., Cherezov, V., Roth, B.L., Stevens, R.C., Molecular control of δ-opioid receptor signalling. Nature 506 (2014), 191–196.
32. Fredriksson, R., Lagerström, M.C., Lundin, L.G., Schiöth, H.B., The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63 (2003), 1256–1272.
33. Gimpl, G., Interaction of G protein coupled receptors and cholesterol. Chem. Phys. Lipids 199 (2016), 61–73.
34. Gloriam, D.E., Foord, S.M., Blaney, F.E., Garland, S.L., Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem. 52 (2009), 4429–4442.
35. Goodman, O.B. Jr., Krupnick, J.G., Santini, F., Gurevich, V.V., Penn, R.B., Gagnon, A.W., Keen, J.H., Benovic, J.L., Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383 (1996), 447–450.
36. Hamann, J., Aust, G., Araç, D., Engel, F.B., Formstone, C., Fredriksson, R., Hall, R.A., Harty, B.L., Kirchhoff, C., Knapp, B., et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol. Rev. 67 (2015), 338–367.
37. Hollenstein, K., Kean, J., Bortolato, A., Cheng, R.K., Doré, A.S., Jazayeri, A., Cooke, R.M., Weir, M., Marshall, F.H., Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499 (2013), 438–443.
38. Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G.W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., Laprairie, R.B., Stahl, E.L., Ho, J.H., Zvonok, N., Zhou, H., Kufareva, I., Wu, B., Zhao, Q., Hanson, M.A., Bohn, L.M., Makriyannis, A., Stevens, R.C., Liu, Z.J., Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 167 (2016), 750–762 e714.
39. Huang, W., Manglik, A., Venkatakrishnan, A.J., Laeremans, T., Feinberg, E.N., Sanborn, A.L., Kato, H.E., Livingston, K.E., Thorsen, T.S., Kling, R.C., et al. Structural insights into μ-opioid receptor activation. Nature 524 (2015), 315–321.
40. Huang, X.P., Karpiak, J., Kroeze, W.K., Zhu, H., Chen, X., Moy, S.S., Saddoris, K.A., Nikolova, V.D., Farrell, M.S., Wang, S., et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527 (2015), 477–483.
41. Irwin, J.J., Shoichet, B.K., ZINC–a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45 (2005), 177–182.
42. Jazayeri, A., Doré, A.S., Lamb, D., Krishnamurthy, H., Southall, S.M., Baig, A.H., Bortolato, A., Koglin, M., Robertson, N.J., Errey, J.C., et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533 (2016), 274–277.
43. Kang, Y., Zhou, X.E., Gao, X., He, Y., Liu, W., Ishchenko, A., Barty, A., White, T.A., Yefanov, O., Han, G.W., et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523 (2015), 561–567.
44. Katritch, V., Cherezov, V., Stevens, R.C., Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 531–556.
45. Katritch, V., Fenalti, G., Abola, E.E., Roth, B.L., Cherezov, V., Stevens, R.C., Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 39 (2014), 233–244.
46. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J., Jensen, N.H., Kuijer, M.B., Matos, R.C., Tran, T.B., et al. Predicting new molecular targets for known drugs. Nature 462 (2009), 175–181.
47. Kenakin, T., Boselli, C., Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. J. Pharmacol. Exp. Ther. 250 (1989), 944–952.
48. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., Novick, S., A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3 (2012), 193–203.
49. Klein Herenbrink, C., Sykes, D.A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P.J., Capuano, B., Sexton, P.M., Charlton, S.J., et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun., 7, 2016, 10842.
50. Kolb, P., Rosenbaum, D.M., Irwin, J.J., Fung, J.J., Kobilka, B.K., Shoichet, B.K., Structure-based discovery of beta2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. USA 106 (2009), 6843–6848.
51. Kruse, A.C., Ring, A.M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P.M., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504 (2013), 101–106.
52. Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., Morikawa, K., Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407 (2000), 971–977.
53. Lafferty-Whyte, K., Mormeneo, D., Del Fresno Marimon, M., Trial watch: Opportunities and challenges of the 2016 target landscape. Nat. Rev. Drug Discov. 16 (2017), 10–11.
54. Lansu, K., Karpiak, J., Liu, J., Huang, X.P., McCorvy, J.D., Kroeze, W.K., Che, T., Nagase, H., Carroll, F.I., Jin, J., et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat. Chem. Biol. 13 (2017), 529–536.
55. Lanzafame, A., Christopoulos, A., Mitchelson, F., Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors. J. Pharmacol. Exp. Ther. 282 (1997), 278–285.
56. Lebon, G., Warne, T., Edwards, P.C., Bennett, K., Langmead, C.J., Leslie, A.G., Tate, C.G., Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474 (2011), 521–525.
57. Lefkowitz, R.J., Shenoy, S.K., Transduction of receptor signals by beta-arrestins. Science 308 (2005), 512–517.
58. Liang, Y.L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J., Thal, D.M., Furness, S.G.B., Christopoulos, G., Coudrat, T., et al. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546 (2017), 118–123.
59. Liu, J.J., Horst, R., Katritch, V., Stevens, R.C., Wüthrich, K., Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335 (2012), 1106–1110.
60. Liu, W., Chun, E., Thompson, A.A., Chubukov, P., Xu, F., Katritch, V., Han, G.W., Roth, C.B., Heitman, L.H., IJzerman, A.P., et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337 (2012), 232–236.
61. Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G., Lefkowitz, R.J., beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248 (1990), 1547–1550.
62. Luttrell, L.M., Ferguson, S.S., Daaka, Y., Miller, W.E., Maudsley, S., Della Rocca, G.J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D.K., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283 (1999), 655–661.
63. Manglik, A., Kim, T.H., Masureel, M., Altenbach, C., Yang, Z., Hilger, D., Lerch, M.T., Kobilka, T.S., Thian, F.S., Hubbell, W.L., et al. Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling. Cell 161 (2015), 1101–1111.
64. Manglik, A., Lin, H., Aryal, D.K., McCorvy, J.D., Dengler, D., Corder, G., Levit, A., Kling, R.C., Bernat, V., Hübner, H., et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537 (2016), 185–190.
65. Mason, J.S., Bortolato, A., Congreve, M., Marshall, F.H., New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol. Sci. 33 (2012), 249–260.
66. McAlear, S.D., Kraft, T.W., Gross, A.K., 1 rhodopsin mutations in congenital night blindness. Adv. Exp. Med. Biol. 664 (2010), 263–272.
67. Moore, A.R., Ceraudo, E., Sher, J.J., Guan, Y., Shoushtari, A.N., Chang, M.T., Zhang, J.Q., Walczak, E.G., Kazmi, M.A., Taylor, B.S., et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat. Genet. 48 (2016), 675–680.
68. Morello, J.P., Salahpour, A., Laperrière, A., Bernier, V., Arthus, M.F., Lonergan, M., Petäjä-Repo, U., Angers, S., Morin, D., Bichet, D.G., Bouvier, M., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105 (2000), 887–895.
69. Ngo, T., Ilatovskiy, A.V., Stewart, A.G., Coleman, J.L., McRobb, F.M., Riek, R.P., Graham, R.M., Abagyan, R., Kufareva, I., Smith, N.J., Orphan receptor ligand discovery by pickpocketing pharmacological neighbors. Nat. Chem. Biol. 13 (2017), 235–242.
70. Noble, M.E., Endicott, J.A., Johnson, L.N., Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004), 1800–1805.
71. Nobles, M., Benians, A., Tinker, A., Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc. Natl. Acad. Sci. USA 102 (2005), 18706–18711.
72. O'Connor, C., White, K.L., Doncescu, N., Didenko, T., Roth, B.L., Czaplicki, G., Stevens, R.C., Wüthrich, K., Milon, A., NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor. Proc. Natl. Acad. Sci. USA 112 (2015), 11852–11857.
73. Oswald, C., Rappas, M., Kean, J., Doré, A.S., Errey, J.C., Bennett, K., Deflorian, F., Christopher, J.A., Jazayeri, A., Mason, J.S., et al. Intracellular allosteric antagonism of the CCR9 receptor. Nature 540 (2016), 462–465.
74. Paek, J., Kalocsay, M., Staus, D.P., Wingler, L., Pascolutti, R., Paulo, J.A., Gygi, S.P., Kruse, A.C., Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling. Cell 169 (2017), 338–349.
75. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289 (2000), 739–745.
76. Pan, Y., Metzenberg, A., Das, S., Jing, B., Gitschier, J., Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat. Genet. 2 (1992), 103–106.
77. Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K.S., Durand, G., Pucci, B., Trinquet, E., et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc. Natl. Acad. Sci. USA 109 (2012), 6733–6738.
78. Rask-Andersen, M., Almén, M.S., Schiöth, H.B., Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10 (2011), 579–590.
79. Rasmussen, S.G., Choi, H.J., Fung, J.J., Pardon, E., Casarosa, P., Chae, P.S., Devree, B.T., Rosenbaum, D.M., Thian, F.S., Kobilka, T.S., et al. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469 (2011), 175–180.
80. Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., Thian, F.S., Chae, P.S., Pardon, E., Calinski, D., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477 (2011), 549–555.
81. Ring, A.M., Manglik, A., Kruse, A.C., Enos, M.D., Weis, W.I., Garcia, K.C., Kobilka, B.K., Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature 502 (2013), 575–579.
82. Roth, B.L., Drugs and valvular heart disease. N. Engl. J. Med. 356 (2007), 6–9.
83. Roth, B.L., DREADDs for Neuroscientists. Neuron 89 (2016), 683–694.
84. Roth, B.L., Kroeze, W.K., Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J. Biol. Chem. 290 (2015), 19471–19477.
85. Roth, B.L., Baner, K., Westkaemper, R., Siebert, D., Rice, K.C., Steinberg, S., Ernsberger, P., Rothman, R.B., Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. USA 99 (2002), 11934–11939.
86. Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004), 353–359.
87. Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, S.J., Roth, B.L., Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 (2000), 2836–2841.
88. Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361 (2009), 1173–1178.
89. Samama, P., Cotecchia, S., Costa, T., Lefkowitz, R.J., A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993), 4625–4636.
90. Scanlan, T.S., Suchland, K.L., Hart, M.E., Chiellini, G., Huang, Y., Kruzich, P.J., Frascarelli, S., Crossley, D.A., Bunzow, J.R., Ronca-Testoni, S., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 10 (2004), 638–642.
91. Shihoya, W., Nishizawa, T., Okuta, A., Tani, K., Dohmae, N., Fujiyoshi, Y., Nureki, O., Doi, T., Activation mechanism of endothelin ETB receptor by endothelin-1. Nature 537 (2016), 363–368.
92. Simon, M.I., Strathmann, M.P., Gautam, N., Diversity of G proteins in signal transduction. Science 252 (1991), 802–808.
93. Smit, M.J., Vischer, H.F., Bakker, R.A., Jongejan, A., Timmerman, H., Pardo, L., Leurs, R., Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 53–87.
94. Staus, D.P., Strachan, R.T., Manglik, A., Pani, B., Kahsai, A.W., Kim, T.H., Wingler, L.M., Ahn, S., Chatterjee, A., Masoudi, A., et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature 535 (2016), 448–452.
95. Tesmer, J.J., Hitchhiking on the heptahelical highway: structure and function of 7TM receptor complexes. Nat. Rev. Mol. Cell Biol. 17 (2016), 439–450.
96. Thomsen, A.R., Plouffe, B., Cahill, T.J. 3rd, Shukla, A.K., Tarrasch, J.T., Dosey, A.M., Kahsai, A.W., Strachan, R.T., Pani, B., Mahoney, J.P., et al. GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling. Cell 166 (2016), 907–919.
97. Urban, J.D., Clarke, W.P., von Zastrow, M., Nichols, D.E., Kobilka, B., Weinstein, H., Javitch, J.A., Roth, B.L., Christopoulos, A., Sexton, P.M., et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2007), 1–13.
98. Urs, N.M., Gee, S.M., Pack, T.F., McCorvy, J.D., Evron, T., Snyder, J.C., Yang, X., Rodriguiz, R.M., Borrelli, E., Wetsel, W.C., et al. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc. Natl. Acad. Sci. USA 113 (2016), E8178–E8186.
99. van der Westhuizen, E.T., Valant, C., Sexton, P.M., Christopoulos, A., Endogenous allosteric modulators of G protein-coupled receptors. J. Pharmacol. Exp. Ther. 353 (2015), 246–260.
100. Vass, M., Kooistra, A.J., Ritschel, T., Leurs, R., de Esch, I.J., de Graaf, C., Molecular interaction fingerprint approaches for GPCR drug discovery. Curr. Opin. Pharmacol. 30 (2016), 59–68.
101. Venkatakrishnan, A.J., Deupi, X., Lebon, G., Tate, C.G., Schertler, G.F., Babu, M.M., Molecular signatures of G-protein-coupled receptors. Nature 494 (2013), 185–194.
102. Violin, J.D., Lefkowitz, R.J., Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28 (2007), 416–422.
103. Wacker, D., Fenalti, G., Brown, M.A., Katritch, V., Abagyan, R., Cherezov, V., Stevens, R.C., Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 132 (2010), 11443–11445.
104. Wacker, D., Wang, C., Katritch, V., Han, G.W., Huang, X.P., Vardy, E., McCorvy, J.D., Jiang, Y., Chu, M., Siu, F.Y., et al. Structural features for functional selectivity at serotonin receptors. Science 340 (2013), 615–619.
105. Wacker, D., Wang, S., McCorvy, J.D., Betz, R.M., Venkatakrishnan, A.J., Levit, A., Lansu, K., Schools, Z.L., Che, T., Nichols, D.E., et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168 (2017), 377–389.
106. Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G.W., Liu, W., Huang, X.P., Vardy, E., et al. Structural basis for molecular recognition at serotonin receptors. Science 340 (2013), 610–614.
107. Wardman, J.H., Gomes, I., Bobeck, E.N., Stockert, J.A., Kapoor, A., Bisignano, P., Gupta, A., Mezei, M., Kumar, S., Filizola, M., Devi, L.A., Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake. Sci. Signal., 9, 2016, ra55.
108. White, J.F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., Gvozdenovic-Jeremic, J., Shah, P., Shiloach, J., Tate, C.G., Grisshammer, R., Structure of the agonist-bound neurotensin receptor. Nature 490 (2012), 508–513.
109. White, K.L., Robinson, J.E., Zhu, H., DiBerto, J.F., Polepally, P.R., Zjawiony, J.K., Nichols, D.E., Malanga, C.J., Roth, B.L., The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J. Pharmacol. Exp. Ther. 352 (2015), 98–109.
110. Zhang, D., Gao, Z.G., Zhang, K., Kiselev, E., Crane, S., Wang, J., Paoletta, S., Yi, C., Ma, L., Zhang, W., et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520 (2015), 317–321.
111. Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J.T., Li, S., Sun Kobilka, T., Kobilka, B.K., Skiniotis, G., Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546 (2017), 248–253.